IBI3001 #ESMO26: first-in-class EGFR/B7-H3 bsADC, Ph1, 53 evaluable
➡️ ORR 30.2%; 45.0% at 8 mg/kg
➡️ EGFRm NSCLC ORR 31.3%, mPFS 7.7 mo
➡️ SCLC ORR 62.5% (n=8)
➡️ G≥3 TRAEs 47.4%
The bsADC wave keeps coming. What does dual targeting add?
@LungCancerRx @OncoAlert @oncodaily
39 views · 0 likes · 0 reposts · 0 replies
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgEarly clinical evidence of VRN110755: A novel brain-penetrant EGFR TKI active across common, uncommon, and resistance EGFR mutations
https://esmocongress.esmo.orgEnozertinib (ORIC-114), a brain penetrant, highly selective EGFR inhibitor, in treatment-naive metastatic NSCLC with EGFR atypical mutations
https://esmocongress.esmo.orgTelisotuzumab adizutecan (temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs)
https://esmocongress.esmo.orgOsimertinib (osi) rechallenge after interstitial lung disease (ILD) during osi treatment (tx) in EGFR-mutated advanced non-small cell lung cancer (NSCLC): A retrospective chart review study
https://esmocongress.esmo.orgDose modifications to manage adverse events (AEs) in 1L EGFR-mutated advanced NSCLC: Post hoc, exploratory analyses from the phase 3 MARIPOSA trial
https://esmocongress.esmo.orgSource: Aakash Desai · x.com